Sacrosidase

Summary

Sacrosidase (CHEMBL1201487) is an approved enzyme (ATC A16AB06).

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Enzyme
• ATC class: A16AB06
• Clinical trials: 2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1201487
Name	Sacrosidase
Type	Enzyme
Max phase	4
ATC	A16AB06

Also known as: .beta.-fructofuranosidase, Sacrosidasa, Sacrosidase, Sucraid, SACROSIDASE

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 2.

Phase distribution

Phase	Trials
PHASE4	1
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02784067	PHASE4	WITHDRAWN	A Trial to Evaluate the Frequency of Genetic Sucrase-Isomaltase Deficiency Genotypes, and the Efficacy and Safety of Sucraid® (Sacrosidase) Oral Solution in Subjects With Chronic Diarrhea and Sucrase Deficiency
NCT05703009	PHASE2	COMPLETED	Effects of Sacrosidase and Placebo in Subjects With Fructan Intolerance

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).